A UK medicine and healthcare regulator could stop the roll-out of the Oxford AstraZeneca Covid vaccine for younger adults amid fears of a rare type of blood clot.
The vaccine will be put through a "thorough and detailed review" by the Medicines and Healthcare products Regulatory Agency to determine its suitability for young adults.
Concerns rose after data emerged suggesting the vaccine could be linked to a rare risk of blood clot with the Astra Zeneca vaccine, Channel 4 reported.
Former SAGE member, Neil Ferguson, said the risk may also be associated at a "lower level with other vaccines too," adding that the risk appears to be age-related.
A decision on whether to halt the rollout for certain ages could be made as early as April 6, but the MHRA said "no decision has yet been made" as of Monday night.
MHRA chief executive, Dr June Raine, said: "People should continue to get their vaccine when invited to do so.
"Our thorough and detailed review is ongoing into reports of very rare and specific types of blood clots with low platelets following the Covid-19 Vaccine AstraZeneca.
"No decision has yet been made on any regulatory action."
Get latest news headlines delivered free
Want all the latest shocking news and views from all over the world straight into your inbox?
We've got the best royal scoops, crime dramas and breaking stories – all delivered in that Daily Star style you love.
Our great newsletters will give you all you need to know, from hard news to that bit of glamour you need every day. They'll drop straight into your inbox and you can unsubscribe whenever you like.
You can sign up here – you won't regret it…
Professor Ferguson said the Medicines and Healthcare products Regulatory Agency (MHRA) and the Joint Committee on Vaccination and Immunisation (JCVI) were "considering this matter very urgently".
He said: "No vaccine, no medicine is risk-free – it is always about a balancing equation against risk."
Two free rapid Covid tests a week for every single person in England from Friday
Several European countries have reviewed the roll-out of the vaccine, with the Netherlands following Germany to suspend the jab to under 60s.
The decision came after MHRA identified 30 cases of rare blood clot events – with seven deaths – out of 18.1 million doses of the AstraZeneca jab administered up to and including March 24 in the UK.
Of the 30 reports, the agency included 22 reports of cerebral venous sinus thrombosis (CVST) – which stops blood draining from the brain properly – and eight of other thrombosis events with low platelets.
Source: Read Full Article